For personal use only

nanosonics

From a proven product, to a multi-platform leader.

Annual General Meeting 2026

4 November 2026



For personal use only

A strongly independent Board with diverse skills



Steven Sargent BBus, FAICD, FTSE
Independent Non-executive Director and Chairman



Michael Kavanagh BSc, MBA (Advanced)
CEO, President and Managing Director



Marie McDonald BSc (Hons), LLB (Hons), FAICD
Independent Non-executive Director



Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow
Independent Non-executive Director



Tracey Batten MBBS, MBA (Harvard), FAICD, MHA, FRACMA
Independent Non-executive Director



Gerard Dalbosco M.AppFin, B.Comm, FCA, FFIN, GAICD
Independent Non-executive Director




Sarah Butler BA(Hons), MA, Adjunct Professor, FAICD
Independent Non-executive Director

For personal use only

How to ask a question


- To ask a written question, select the Q & A icon.
- Select the topic your question relates to from the drop-down list.
- Type your question in the text box and press the send icon.
- To ask a verbal question follow the instructions below the broadcast window.



For personal use only

How to vote

- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote “click here to change your vote” at any time until the poll is closed



For personal use only

Chairman's Address

Steve Sargent

Non-executive Director
and Chairman



Our focus is infection prevention

Our mission is to improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted by introducing innovative technologies that deliver improved standards of care.

Delivering trusted care

Out-engineering infection risk

Shaping global standards



31 million
patients protected in FY26

For personal use only

For personal use only

Evolving infection prevention environment

Leveraging its expertise in automation, medical reprocessing and digitisation, Nanosonics is leading the way to support healthcare providers to protect more patients.

INFECTION PREVENTION DYNAMICS

- Technology advancements
- Expanding clinical applications
- Hospital budget pressures & inflation
- Contamination risk reduction
- Cybersecurity

Driving solutions that are

nanosonics

- Safer for patients
- Automated & workflow efficient
- More effective & validated
- Digital & safe
- Compliant & audit-ready

For personal use only

Driving value creation

Nanosonics is entering a defining period of growth

trophon business model & performance

- Growing revenue & EBIT in constant currency
- Disciplined capital allocation
- Improving operating leverage
- Strong cash generation
- High return on capital in trophon-only business

Creates opportunities for tomorrow

- **Product growth & expansion**
- **CORIS commercialisation**
- **Market expansion**



Our commitment to sustainability

Caring for our customers and their patients, our partners, our people, the planet and the community.

51%

reduction in Scope 1 and 2 emissions in FY26

80% reduction
over the past 2 years



For personal use only

For personal use only

A strongly independent Board with diverse skills



Steven Sargent BBus, FAICD, FTSE
Independent Non-executive Director and Chairman



Michael Kavanagh BSc, MBA (Advanced)
CEO, President and Managing Director



Marie McDonald BSc (Hons), LLB (Hons), FAICD
Independent Non-executive Director



Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow
Independent Non-executive Director



Tracey Batten MBBS, MBA (Harvard), FAICD, MHA, FRACMA
Independent Non-executive Director



Gerard Dalbosco M.AppFin, B.Comm, FCA, FFIN, GAICD
Independent Non-executive Director



Sarah Butler BA(Hons), MA, Adjunct Professor, FAICD
Independent Non-executive Director

For personal use only

Newly announced independent Non-executive Board member



Julien Sauvagnargues

Independent Non-executive Director

Joining the Nanosonics Board on 1 December 2026

- Global MedTech executive
- Two decades at Olympus
- European and North American experience
- Commercial, growth and operational experience

For personal use only

From one proven platform to a multi-platform leader

Building the future of automated infection prevention



CEO Address

Michael Kavanagh

CEO, President and
Managing Director

Led by an experienced team

For personal use only



Michael Kavanagh BSc, MBA (Advanced)
CEO, President and Managing Director



Jason Burriss BCom, CA
Chief Financial Officer



Kimberly Hill BSc
Chief Marketing Officer & Regional President, Asia Pacific



Rod Lopez MBA, BEng (Hons), GAICD
Chief Operating Officer



Matthew Carbines LLB, Bcom
General Counsel & Company Secretary



Jodi Sampson MBA(Exec), CPHR, MAICD
Chief People and Culture Officer



Derek Minihane BSEE, JD
Chief Technology Officer



Jon Burdach, BBioMedSc (Hons), PhD
Chief Medical Affairs & Scientific Officer



Bill Haydon BA, MBA
Regional President, North America



Sunny Pillai MBA, BEng(Hons)
Chief Information Officer



Ronan Wright BSc, Bus Management, Beng
Regional President, Europe Middle East & Africa

FY26: underlying growth, disciplined execution

A strong core business continued to fund investment in the next platform.

$203.9m	$211.5m	76.9%	$21.6m	$155.2m
reported revenue	**revenue at CC**	**gross margin**	**EBIT at CC**	**cash**
3% growth	6% growth	77.6% at CC	21% growth	no debt

Core franchise strength

4,230 trophon placements, up 9%. The installed base grew 6% to 39,230 devices.

Investment with discipline

$31.8m invested in R&D while total operating expense of $141.4M was held to 2% growth.

Capital flexibility

$13.6m business cash flow excluding the FY26 buy back, with balance sheet capacity to fund growth.

FY26 delivered continued trophon growth while investing in the next phase of expansion.

For personal use only

For personal use only

nanosonics

Core trophon-only business profitability growing strongly

Generating cash and funding next platform growth.

Sustained EBIT growth and high-quality cash conversion in the trophon-only business demonstrates durability and provides self-funded capacity for the next phase of growth.

EBIT

$50.6M

▲ 5% on pcp

EBIT in CC

$56.5M

▲ 16% CC



For personal use only

FY26 delivery positioned Nanosonics for its next phase

Disciplined operational execution laid the foundations for the next phase of growth

TROPHON

trophon3 and trophon2 Plus launched; adoption accelerated in the second half.

CORIS

Clearances across Australia, Europe and the UK; first expanded US indication cleared.

OPERATIONS

US consumables manufacturing established and Australian CORIS device manufacturing readied.

DIGITAL

Connectivity and traceability capabilities expanded to deepen customer workflow value.

FY26 delivered key operational milestones to support the next phase of growth.

For personal use only

Nanosonics reaffirms FY27 guidance

Q1 FY27 performance is consistent with Nanosonics' expectations.

FY27 guidance at constant currency

Revenue	**$220 million to $228 million**, reflecting 8% to 12% growth on FY26.
Gross Profit %	**74%-76%**
Operational expenses	**$156 million to $163 million**, reflecting 10% to 15% growth on FY26.



Guidance is at constant currency, using a USD/AUD exchange rate of 0.68. Nanosonics generates the majority of its revenue in USD. If the Revenue range in the above table were recast using an average exchange rate for USD/AUD of 0.71 FY27, rather than constant currency, and the hedging program is taken into account, the Revenue range would be approximately $3 million lower. Guidance assumes no changes to the global trading environment and US tariffs at current level of 12.5%. All guidance is subject to uncertainty in relation to potential impacts associated with macroeconomic and political uncertainty, as well as potential impacts from increased competitive activity in the USA.

From a successful single-platform company to a repeatable platform company

For personal use only

Build
from trophon.

trophon
PROVEN CORE

Scale
CORIS.

CORIS
SECOND PLATFORM

Repeat
our capability selectively.

FUTURE
PLATFORMS

nanosonics

The opportunity is to automate what healthcare still performs manually

Manual variability, fragmented records and workforce pressure create a broad class of problems to solve.

AUTOMATE	Replace technique-dependent work with automated workflows
STANDARDISE	Deliver repeatable performance across people and sites
VALIDATE	Make outcomes measurable, defensible and audit-ready
CONNECT	Create cycle-level traceability and workflow insight

A focused strategic space with room for multiple platforms



For personal use only

The capability system to deliver our growth strategy

Integrated expertise supports each platform from clinical need through to commercial scale.

R&D + engineering -
Platform, product, software and consumables

Clinical + medical –
Need definition, evidence and adoption

Bioscience – biological models and testing

Regulatory + quality -
Global clearances and validated systems

Manufacturing + supply -
Devices, consumables and resilient scale

Digital + connectivity -
Traceability, insight and workflow data

Commercial + service -
Implementation, training and lifecycle support



For personal use only

trophon still has a substantial runway for profitable growth

The platform can compound through installed base, upgrades, utilisation and lifetime value.

39,230
installed base
6% FY26 growth

8,000
EPR upgrade opportunity
remaining in North America

$149.2m
recurring revenue
FY26 reported

$50.6m
trophon-only EBIT
16% CC growth

CAPITAL REVENUE

01 New installed base device sales, trophon3



02 Upgrade capital sales

03 Capital software upgrades, trophon2 *Plus*





RECURRING REVENUE

04 Core consumables



05 Ecosystem consumables



06 Service



07 Connectivity subscriptions



More devices × more utilisation × more ecosystem value × more upgrades and service.

Geographic expansion opportunity remains beyond current markets.

For personal use only

nanosonics
CORIS

For personal use only

It’s time for a better clean

Nanosonics CORIS® System.

A new era in flexible endoscope reprocessing starts here.



For personal use only

A critical cleaning step, manual methods cannot reliably complete

Cleaning is the critical first step in reprocessing flexible endoscopes, yet it remains manual, variable and unverified. The CORIS System automates it.


THE PROBLEM

Manual cleaning cannot reach every channel

Unreachable channels Narrow and branched channels are difficult or impossible to brush and flushing alone may not remove contamination.

Biofilm persists Contamination and biofilm can remain inside channels even when protocols are followed, creating patient safety risk.

Variable and unverified Outcomes vary between individuals, shifts and workloads, with documentation covering only selected steps.



THE SOLUTION

The CORIS System automates and verifies the cleaning step

A new benchmark in efficacy Delivers the physical friction required to remove soil and biofilm from narrow, branched and unbrushable channels.

Protects reprocessing teams Designed to reduce physical burden and exposure to chemicals and infectious materials via an automated, closed system workflow.

Engineered for consistency Standardises a critical step, reducing variability and supporting repeatable outcomes across every site.

Traceable every cycle Captures validated cleaning parameters for each cycle, supporting verification and audit readiness.

Smarter Workflows Minimises labour-intensive manual steps, helping teams to focus on quality, compliance and other essential tasks.



CORIS automates the one step in endoscope reprocessing that has remained manual, variable and unverified.

Large CORIS recurring revenue opportunity

Capital, consumables and service compound as the installed base grows, leveraging the same annuity model as trophon.

For personal use only

>60M

procedural TAM[1] across key regions

FY27 launch markets

UNITED KINGDOM & IRELAND
>5M procedure opportunity

AUSTRALIA
>2M procedure opportunity

UNITED STATES
>34M procedure opportunity

CAPITAL & ACCESSORIES

3-5X TROPHON

capital price

Mix of capital sales and other selling models.

UTILISATION

~10

cycles per device per day

High volume sites may have 3-4 units in Central Sterile Department.

CONSUMABLES

4-6X TROPHON

price per cycle

Price will vary based on purchase model & market.

SERVICE

~80%

attachment rate

Customer opt-in, expected to be high post 1 year warranty.

Note: Indicative metrics are early stage estimates, subject to change as commercial experience builds.

For personal use only



For personal use only

The CORIS System is delivering a consistently positive staff experience

UK CMR site feedback highlights strong workflow, usability and confidence in routine adoption

OVERALL RESULT

4.87

/ 5 average statement score

100%

positive on routine adoption


Survey of the 6 CORIS CMR site users.

Workflow & capacity	• Reduced hands-on manual cleaning • Staff time can be redirected • Smoother, more predictable workflow • Helps manage peaks in endoscope demand	**4.65 / 5** 95% positive
Usability & workforce	• Easy to learn and follow • High confidence running a CORIS cycle • Reduces demanding, repetitive activity • Improves day-to-day working experience	**5.00 / 5** 100% positive
Consistency, quality & adoption	• More consistent than manual cleaning alone • Confidence that required steps are completed • Fits practically within the department • Strong support for routine adoption	**4.95 / 5** 99.9% positive

For personal use only

UK & Ireland CORIS launch

Manchester Science & Industry Museum









nanosonics
CORIS

Nanosonics CORIS®
System wins

GOOD
DESIGN
AWARD®
GOLD WINNER


Medical & Scientific category



For personal use only

THE NANOSONICS VISION

A multi-platform leader in automated infection prevention



Building on trophon's success to deliver the next phase of growth in automated infection prevention.

For personal use only



AGM 2026 Resolutions

For personal use only

Resolution 1

Election of a Director, Ms Sarah Butler



Sarah Butler FAICD
Independent Non-executive Director

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That Ms Sarah Butler, who was appointed as a Director by the Board on 20 January 2026 and retires as a Director in accordance with the Constitution and ASX Listing Rule 14.4 and, being eligible for election (and offering her self for election), be elected as a Director.

Proxy votes received	Number	%
For:	190,344,935	99.85
Against:	123,207	0.06
Discretion:	176,727	0.09
Abstained/Excluded:	55,681	N/A

For personal use only

Resolution 2

Re-election of a Director, Dr Larry Marshall



Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow
Independent Non-executive Director

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That Dr Larry Marshall, who retires as a Director by rotation in accordance with the Constitution and ASX Listing Rule 14.4 and, being eligible for re-election (and offering himself for re-election), be re-elected as a Director.

Proxy votes received	Number	%
For:	188,790,044	99.02
Against:	1,672,748	0.88
Discretion:	183,077	0.10
Abstained/Excluded:	54,681	N/A

For personal use only

Resolution 3

Re-election of a Director, Dr Tracey Batten



Tracey Batten MBBS, MBA (Harvard), FAICD, MHA, FRACMA
Independent Non-executive Director

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That Dr Tracey Batten, who retires as a Director by rotation in accordance with the Constitution and ASX Listing Rule 14.4 and, being eligible for re-election (and offering herself for re-election), be re-elected as a Director.

Proxy votes received	Number	%
For:	182,779,942	95.88
Against:	7,681,900	4.03
Discretion:	176,927	0.09
Abstained/Excluded:	61,781	N/A

For personal use only

Resolution 4

Adoption of Remuneration Report

To consider and, if thought fit, to pass the following advisory, non-binding resolution (in accordance with section 250R(3) of the Corporations Act) as an ordinary resolution:

That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 30 June 2026 (as contained in the Directors Report) be adopted.

Proxy votes received	Number	%
For:	176,928,088	94.16
Against:	10,735,949	5.71
Discretion:	242,782	0.13
Abstained/Excluded:	2,793,731	N/A

For personal use only

Resolution 5

Issue of 70,833 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh's 2026 Short Term Incentive grant (FY26 STI) and under the Nanosonics Equity Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That approval be given under and for the purpose of ASX Listing Rule 10.14 and for all other purposes for the issue of 70,833 Service Rights to Nanosonics' Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh's FY26 STI, on the terms and conditions summarised in the Explanatory Notes accompanying this Notice of Meeting and the Nanosonics Equity Plan Rules (as amended from time-to-time).

Proxy votes received	Number	%
For:	181,438,403	96.54
Against:	6,294,918	3.35
Discretion:	199,727	0.11
Abstained/Excluded:	2,767,502	N/A

For personal use only

Resolution 6

Issue of 625,363 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh's FY27 Long-Term Incentive grant (FY27 LTI) and under the Nanosonics Equity Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That approval be given under and for the purpose of ASX Listing Rule 10.14 and for all other purposes for the issue of 625,363 Performance Rights to Nanosonics' Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh's FY27 LTI, on the terms and conditions summarised in the Explanatory Notes accompanying this Notice of Meeting and he Nanosonics Equity Plan Rules (as amended from time-to-time).

Proxy votes received	Number	%
For:	180,938,628	96.28
Against:	6,794,292	3.61
Discretion:	197,653	0.11
Abstained/Excluded:	2,769,977	N/A

For personal use only

Resolution 7

Approval of the Nanosonics Equity Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

That, for the purpose of ASX Listing Rule 7.2 (Exception 13) and for all other purposes, the Nanosonics Equity Plan (the terms and conditions of which are summarised in the Explanatory Notes accompanying this Notice of Meeting), and the issue of securities under the Nanosonics Equity Plan as an exception to ASX Listing Rule 7.1 (including the maximum number of equity securities proposed to be issued under the Nanosonics Equity Plan within the 3-year period commencing on the date of the passing of this Resolution) as described in the Explanatory Notes accompanying this Notice of Meeting, be approved.

Proxy votes received	Number	%
For:	183,386,273	97.58
Against:	4,352,283	2.32
Discretion:	194,727	0.10
Abstained/Excluded:	2,767,267	N/A

For personal use only

Resolution 8

Increase in maximum aggregate Non-Executive Directors' Remuneration

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:


That, for the purposes of clauses 22.1 and 22.8 of the Company's Constitution and ASX Listing Rule 10.17 (and for all other purposes), the maximum aggregate Remuneration (including directors' fees specified in ASX Listing Rule 10.17) that may be provided to or for the benefit of the Non-Executive Directors in any financial year of the Company be increased by $400,000 from $1,200,000 to $1,600,000.

Proxy votes received	Number	%
For:	183,525,283	97.54
Against:	4,450,646	2.36
Discretion:	195,227	0.10
Abstained/Excluded:	2,529,394	N/A

For personal use only

How to ask a question


- To ask a written question, select the Q & A icon.
- Select the topic your question relates to from the drop-down list.
- Type your question in the text box and press the send icon.
- To ask a verbal question follow the instructions below the broadcast window.



For personal use only

How to vote


- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote “click here to change your vote” at any time until the poll is closed



For personal use only

How to ask a question

- To ask a written question, select the Q & A icon.
- Select the topic your question relates to from the drop-down list.
- Type your question in the text box and press the send icon.
- To ask a verbal question follow the instructions below the broadcast window.



Thank you



For personal use only

Nanosonics Limited
7-11 Talavera Road
Macquarie Park,
NSW 2113 Australia

T +61 2 8063 1600
E info@nanosonics.com.au

www.nanosonics.com.au

ABN 11 095 076 896

For personal use only

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Nanosonics Limited (Nanosonics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement or estimate by any person (including Nanosonics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved.

Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Nanosonics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials.

trophon®, CORIS® and Nanosonics Connect® are registered trade marks of Nanosonics Limited.